Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $4.86, but opened at $5.10. Autolus Therapeutics shares last traded at $4.88, with a volume of 43,610 shares changing hands.

Wall Street Analyst Weigh In

AUTL has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Friday, April 12th. Truist Financial raised their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $8.16.

Autolus Therapeutics Trading Down 0.8 %

The business has a fifty day moving average of $5.93 and a 200 day moving average of $5.08. The company has a market capitalization of $1.28 billion, a PE ratio of -4.03 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). Equities analysts forecast that Autolus Therapeutics plc will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Perpetual Ltd boosted its stake in shares of Autolus Therapeutics by 8.2% in the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after buying an additional 169,784 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Autolus Therapeutics by 97.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 131,731 shares of the company’s stock valued at $848,000 after buying an additional 64,910 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $11,793,000. Sierra Summit Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $275,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $19,328,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.